NCT01566773View on ClinicalTrials.gov

PT001 MDI Versus Spiriva® in Patients With Moderate to Severe COPD

PHASE2CompletedINTERVENTIONAL
Enrollment

140

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

August 31, 2012

Study Completion Date

August 31, 2012

Conditions
Chronic Obstructive Pulmonary Disease
Interventions
DRUG

PT001 MDI

Administered as two puffs BID for 14 days

DRUG

Tiotropium Bromide

Taken as 1 capsule containing 18 µg of tiotropium via the Handihaler DPI

DRUG

PT001 Placebo MDI

Trial Locations (10)

23225

Pearl Investigative Site, Richmond

28207

Pearl Investigative Site, Charlotte

29303

Pearl Investigative Site, Spartanburg

32405

Pearl Investigative Site, Panama City

32789

Pearl Investigative Site, Winter Park

33603

Pearl Investigative Site, Tampa

33765

Pearl Investigative Site, Clearwater

75605

Pearl Investigative Site, Longview

92835

Pearl Investigative Site, Fullerton

97504

Pearl Investigative Site, Medford

Sponsors
All Listed Sponsors
lead

Pearl Therapeutics, Inc.

INDUSTRY